a Sanofi company, announced today that the European Commission (EC) has
granted marketing authorization for Cerdelga ® (INN:
eliglustat) capsules, a first line oral therapy for certain adults
living with Gaucher disease type 1.
for European Commission Grants Marketing Authorization for Cerdelga® (eliglustat), Genzyme’s Oral Therapy for Gaucher Disease Type 1 investment picks